Suppr超能文献

胰岛淀粉样多肽受体:阿尔茨海默病的潜在治疗靶点。

Amylin Receptor: A Potential Therapeutic Target for Alzheimer's Disease.

机构信息

Department of Medicine (Neurology), Neuroscience and Mental Health Institute, University of Alberta, Edmonton, AB, Canada.

Faculty of Engineering, Tokyo University of Science, Yamaguchi, Sanyo-onoda, Yamaguchi, Japan.

出版信息

Trends Mol Med. 2017 Aug;23(8):709-720. doi: 10.1016/j.molmed.2017.06.003. Epub 2017 Jul 7.

Abstract

Alzheimer'sdisease (AD) is a progressive neurodegenerative disorder, characterized by senile plaques constituting extracellular deposits of β-amyloid (Aβ) fibrils. Since Aβ accumulation in the brain is considered an early event preceding, by decades, cognitive dysfunction, disease-modifying treatments are aimed at facilitating clearance of this protein from the brain or ameliorating its toxic effects. Recent studies have identified the amylin receptor as a capable mediator of the deleterious actions of Aβ and furthermore, administration of amylin receptor-based peptides has been shown to improve spatial memory and learning in transgenic mouse models of AD. Here, by discussing available evidence, we posit that the amylin receptor could be considered a potential therapeutic target for AD, and present the rationale for using amylin receptor antagonists to treat this debilitating condition.

摘要

阿尔茨海默病(AD)是一种进行性神经退行性疾病,其特征是由β-淀粉样蛋白(Aβ)原纤维构成的细胞外沉积物的老年斑。由于脑内 Aβ的积累被认为是认知功能障碍发生之前的早期事件,因此改变疾病进程的治疗方法旨在促进该蛋白从大脑中清除或改善其毒性作用。最近的研究已经确定了胰岛淀粉样肽受体作为 Aβ的有害作用的有效介质,此外,胰岛淀粉样肽受体衍生肽的给药已被证明可以改善 AD 转基因小鼠模型的空间记忆和学习能力。在这里,我们通过讨论现有证据,提出胰岛淀粉样肽受体可以被认为是 AD 的潜在治疗靶点,并提出使用胰岛淀粉样肽受体拮抗剂治疗这种使人衰弱的疾病的基本原理。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验